Venetoclax Monotherapy for the Treatment of Multiple Myeloma

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Shaji Kumar, MD, describes the mechanism of action of BCL-2 inhibitor venetoclax and clinical trial data on its efficacy in multiple myeloma.

Related Videos
Hans Hammers, MD, PhD, an expert on renal cell carcinoma
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Related Content